Healthcare provider profile · identity verified

Enna R. Serina, MD

Family Practice · RIVERSIDE, CA · NPI 1356400931

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	527	182
Levothyroxine Sodium	Levothyroxine Sodium	277	93
Amlodipine Besylate	Amlodipine Besylate	253	88
Lisinopril	Lisinopril	182	60
Losartan Potassium	Losartan Potassium	179	56
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	145	31
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	133	48
Metformin Hcl	Metformin Hcl	131	43
Meloxicam	Meloxicam	122	53
Atenolol	Atenolol	110	35
Simvastatin	Simvastatin	109	37
Alendronate Sodium	Alendronate Sodium	94	33
Glipizide	Glipizide	87	35
Omeprazole	Omeprazole	85	25
Rosuvastatin Calcium	Rosuvastatin Calcium	83	30
Terazosin Hcl	Terazosin Hcl	74	23
Potassium Chloride	Potassium Chloride	70	23
Hydrochlorothiazide	Hydrochlorothiazide	67	26
Metoprolol Tartrate	Metoprolol Tartrate	67	23
Albuterol Sulfate Hfa	Albuterol Sulfate	64	45
Gabapentin	Gabapentin	59	24
Humulin N	Insulin Nph Human Isophane	58	19
Ibuprofen	Ibuprofen	51	20
Metformin Hcl Er	Metformin Hcl	51	19
Montelukast Sodium	Montelukast Sodium	46	12
Morphine Sulfate Er	Morphine Sulfate	45	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	45	13
Buspirone Hcl	Buspirone Hcl	44	21
Trazodone Hcl	Trazodone Hcl	44	16
Triamcinolone Acetonide	Triamcinolone Acetonide	44	20
Furosemide	Furosemide	43	22
Pradaxa	Dabigatran Etexilate Mesylate	41	12
Acyclovir	Acyclovir	40	13
Lactulose	Lactulose	39	suppressed
Trospium Chloride	Trospium Chloride	38	13
Fluoxetine Hcl	Fluoxetine Hcl	35	12
Hydralazine Hcl	Hydralazine Hcl	34	suppressed
Morphine Sulfate	Morphine Sulfate	34	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	34	15
Sertraline Hcl	Sertraline Hcl	33	12
Ozempic	Semaglutide	30	suppressed
Tramadol Hcl	Tramadol Hcl	28	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	26	suppressed
Citalopram Hbr	Citalopram Hydrobromide	25	suppressed
Famotidine	Famotidine	23	suppressed
Hydrocortisone	Hydrocortisone	23	16
Prednisone	Prednisone	23	20
Tizanidine Hcl	Tizanidine Hcl	23	suppressed
Carvedilol	Carvedilol	22	suppressed
Estradiol	Estradiol	22	15
Humulin R	Insulin Regular, Human	22	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	22	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	22	suppressed
Clopidogrel	Clopidogrel Bisulfate	21	suppressed
Jardiance	Empagliflozin	21	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	21	suppressed
Alvesco	Ciclesonide	20	13
Ezetimibe	Ezetimibe	20	suppressed
Lovastatin	Lovastatin	20	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	20	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	20	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Ondansetron Hcl	Ondansetron Hcl	19	suppressed
Allopurinol	Allopurinol	18	suppressed
Eliquis	Apixaban	18	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	17	17
Nystatin	Nystatin	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	16	suppressed
Mupirocin	Mupirocin	16	suppressed
Pravastatin Sodium	Pravastatin Sodium	16	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	15	15
Escitalopram Oxalate	Escitalopram Oxalate	15	suppressed
Clobetasol Propionate	Clobetasol Propionate	14	suppressed
Diazepam	Diazepam	14	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	14	suppressed
Cefadroxil	Cefadroxil	13	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Fluticasone Propionate	Fluticasone Propionate	13	suppressed
Acarbose	Acarbose	12	suppressed
Alprazolam	Alprazolam	12	suppressed
Azelastine Hcl	Azelastine Hcl	12	suppressed
Clindamycin Hcl	Clindamycin Hcl	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	12	suppressed
Cephalexin	Cephalexin	11	11
Spironolactone	Spironolactone	11	suppressed
Temazepam	Temazepam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error